(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
5 June 2008 (05.06.2008)

PCT

(10) International Publication Number
WO 2008/066776 A2

(51) International Patent Classification:
C12N 15/11 (2006.01)

(21) International Application Number:
PCT/US2007/024369

(22) International Filing Date:
27 November 2007 (27.11.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/867,395	27 November 2006 (27.11.2006)	US
60/912,892	19 April 2007 (19.04.2007)	US
60/986,286	7 November 2007 (07.11.2007)	US
60/988,074	14 November 2007 (14.11.2007)	US

(71) Applicant *(for all designated States except US)*: **ISIS PHARMACEUTICALS, INC.** [US/US]; 1896 Rutherford Road, Carlsbad, California 92008 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **FREIER, Susan, M.** [US/US]; c/o Isis Pharmaceuticals, Inc., 1896 Rutherford Road, Carlsbad, California 92008 (US). **CROOKE, Rosanne, M.** [US/US]; c/o Isis Pharmaceuticals, Inc., 1896 Rutherford Road, Carlsbad, California 92008 (US). **GRAHAM, Mark, J.** [US/US]; c/o Isis Pharmaceuticals, Inc., 1896 Rutherford Road, Carlsbad, California 92008 (US). **TARBET, Kristina Lemonidis** [US/US]; c/o Isis Pharmaceuticals, Inc., 1896 Rutherford Road, Carlsbad, California 92008 (US). **BHANOT, Sanjay** [US/US]; c/o Isis Pharmaceuticals, Inc., 1896 Rutherford Road, Carlsbad, California 92008 (US). **TRIBBLE, Diane** [US/US]; c/o Isis Pharmaceuticals, Inc., 1896 Rutherford Road, Carlsbad, California 92008 (US). **WATTS, Andrew, T.** [US/US]; c/o Isis Pharmaceuticals, Inc., 1896 Rutherford Road, Carlsbad, California 92008 (US).

(74) Agents: **MEYER, Mercedes, K.** et al.; c/o Drinker Biddle & Reath LLP, 1500 K Street, NW, Suite 1100, Washington, District Of Columbia 20005-1209 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report*

— *with sequence listing part of description published separately in electronic form and available upon request from the International Bureau*

(54) **Title:** METHODS FOR TREATING HYPERCHOLESTEROLEMIA

(57) **Abstract:** Disclosed herein are antisense compounds and methods for decreasing LDL-C in an individual having elevated LDL-C. Additionally disclosed are antisense compounds and methods for treating hypercholesterolemia, or alternatively for treating or preventing atherosclerosis. Further disclosed are antisense compounds and methods for decreasing coronary heart disease risk. Such methods include administering to an individual in need of treatment an antisense compound targeted to a PCSK9 nucleic acid. The antisense compounds administered include gapmer antisense oligonucleotides.

WO 2008/066776 A2